secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001193125-23-277985
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea recasts FY2022 financials for 1-for-25 reverse split; going concern warning persists
--------------------------------------------------------------------------------

- 1-for-25 reverse stock split effective Sept 8, 2023; authorized shares cut from 500M to 20M.
- Recast FY2022 net loss $83.8M ($24.86/share) on total revenue of $2.3M.
- Accumulated deficit $425.6M as of Dec 31, 2022; cash & securities $57.3M.
- Substantial doubt about going concern; cash expected to fund only into Q4 2023.
- Auditor's opinion includes going concern emphasis paragraph.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523277985/0001193125-23-277985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523277985/d361815d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-277985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer